INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA

Alexander Schonfeld; Amihai Schattner; Madeleine Crespi; Hanoch Levavi; Jacob Shoham; Schmuel Nitke; David Wallach; Talia Hahn; Ovadia Yarden; Thomas Doerner; Michet Revel

doi:10.1016/s0140-6736(84)91450-8

INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA

Alexander Schonfeld
, Amihai Schattner
, Madeleine Crespi
, Hanoch Levavi
, Jacob Shoham
, Schmuel Nitke
, David Wallach
, Talia Hahn
, Ovadia Yarden
, Thomas Doerner
, Michet Revel

Weizmann Institute of Science
Rabin Medical Center Israel

Research output: Contribution to journal › Article › peer-review

139 Scopus citations

Abstract

A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×10⁶ units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.

Original language	English
Pages (from-to)	1038-1042
Number of pages	5
Journal	The Lancet
Volume	323
Issue number	8385
DOIs	https://doi.org/10.1016/s0140-6736(84)91450-8
State	Published - 12 May 1984
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported by InterYeda Ltd, Israel.

Funding

This work was supported by InterYeda Ltd, Israel.

Funders
InterYeda Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/s0140-6736(84)91450-8

Cite this

@article{a11474d5aa9a4653995e4c9bc9fecdd7,

title = "INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA",

abstract = "A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×106 units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.",

author = "Alexander Schonfeld and Amihai Schattner and Madeleine Crespi and Hanoch Levavi and Jacob Shoham and Schmuel Nitke and David Wallach and Talia Hahn and Ovadia Yarden and Thomas Doerner and Michet Revel",

note = "Funding Information: This work was supported by InterYeda Ltd, Israel.",

year = "1984",

month = may,

day = "12",

doi = "10.1016/s0140-6736(84)91450-8",

language = "אנגלית",

volume = "323",

pages = "1038--1042",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8385",

}

TY - JOUR

T1 - INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA

AU - Schonfeld, Alexander

AU - Schattner, Amihai

AU - Crespi, Madeleine

AU - Levavi, Hanoch

AU - Shoham, Jacob

AU - Nitke, Schmuel

AU - Wallach, David

AU - Hahn, Talia

AU - Yarden, Ovadia

AU - Doerner, Thomas

AU - Revel, Michet

N1 - Funding Information: This work was supported by InterYeda Ltd, Israel.

PY - 1984/5/12

Y1 - 1984/5/12

N2 - A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×106 units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.

AB - A two-part study was done to assess the value of human fibroblast interferon (IFN-β) in the treatment of condylomata acuminata. The first part was an open study of different IFN-β preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-β. In the double-blind placebo section 22 patients were given injections of 2×106 units IFN-β or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-β group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-β and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5') oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-β produce a systemic response.

UR - https://www.scopus.com/pages/publications/0021348217

U2 - 10.1016/s0140-6736(84)91450-8

DO - 10.1016/s0140-6736(84)91450-8

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 6143975

AN - SCOPUS:0021348217

SN - 0140-6736

VL - 323

SP - 1038

EP - 1042

JO - The Lancet

JF - The Lancet

IS - 8385

ER -

INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this